Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New app aims to ease daily struggles for kidney dialysis patients

NCT ID NCT07211100

Symptom relief Sponsor: Saglik Bilimleri Universitesi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a mobile app designed for people on hemodialysis. The app helps with medication, diet, fluid limits, and symptom tracking. 72 adults will be split into two groups: one uses the app, the other gets standard care. Researchers will check if the app improves treatment adherence and reduces symptoms like fatigue and itching over two months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mobile health application
What this could lead to
If it works, this app could help hemodialysis patients better manage their diet, fluids, and symptoms, improving daily life and treatment adherence.
What could go wrong
This is a small, early-stage study with only 72 people over 2 months. The app may not show clear benefits, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2025

An estimate. Start dates often move.

Expected to finish

Feb 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years. * Diagnosed with end-stage renal disease (ESRD). * Receiving maintenance hemodialysis treatment for at least 3 months. * Able to use a smartphone and willing to install the mobile health application. * Voluntarily agreeing to participate in the study and providing written informed consent. Exclusion Criteria: * Patients with cognitive impairment, severe psychiatric disorders, or communication barriers that may interfere with participation. * Patients with visual or hearing impairments that prevent the use of the mobile application. * Patients who have undergone kidney transplantation or are scheduled for transplantation within the study period. * Patients with serious comorbid conditions requiring hospitalization (e.g., advanced cancer, severe heart failure). * Participation in another interventional clinical trial within the past 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage renal disease requiring haemodialysis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure Fatigue Pain Pruritus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End-stage renal disease requiring haemodialysis Mobile application

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Gumushane State Hospital

    Gümüşhane, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.